Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 200

1.
2.

Hypertension Control Rate Should be Defined Consistently and Used to Motivate Action to Improve.

DeMarzo AP.

High Blood Press Cardiovasc Prev. 2019 Dec;26(6):545-548. doi: 10.1007/s40292-019-00350-4. Epub 2019 Nov 19.

PMID:
31745736
3.

Polypill for Cardiovascular Disease Prevention in an Underserved Population.

Muñoz D, Uzoije P, Reynolds C, Miller R, Walkley D, Pappalardo S, Tousey P, Munro H, Gonzales H, Song W, White C, Blot WJ, Wang TJ.

N Engl J Med. 2019 Sep 19;381(12):1114-1123. doi: 10.1056/NEJMoa1815359.

PMID:
31532959
4.

Six Month Polypill Therapy Improves Lipid Profile in Patients with Previous Acute Myocardial Infarction: The Heart-Mex Study.

Méndez-García LA, González-Chávez A, Trejo-Millán F, Navarrete-Zarco HU, Carrero-Aguirre M, Meléndez G, Chávez A, Escobedo G.

Arch Med Res. 2019 May;50(4):197-206. doi: 10.1016/j.arcmed.2019.08.002. Epub 2019 Sep 26.

PMID:
31499480
5.

Barriers and Facilitators to the Use of Cardiovascular Fixed-Dose Combination Medication (Polypills) in Andhra Pradesh, India: A Mixed-Methods Study.

Salam A, Praveen D, Patel A, Tewari A, Webster R.

Glob Heart. 2019 Sep;14(3):303-310. doi: 10.1016/j.gheart.2019.07.002.

PMID:
31451238
6.

Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.

Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, Ostovaneh MR, Nateghi A, Majed M, Navabakhsh B, Merat S, Pourshams A, Nalini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadegan N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng KK, Malekzadeh R.

Lancet. 2019 Aug 24;394(10199):672-683. doi: 10.1016/S0140-6736(19)31791-X.

PMID:
31448738
7.

Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study.

Castellano JM, Verdejo J, Ocampo S, Rios MM, Gómez-Álvarez E, Borrayo G, Ruiz E, Ibáñez B, Fuster V; SORS investigators.

Arch Med Res. 2019 Jan;50(1):31-40. doi: 10.1016/j.arcmed.2019.04.001. Epub 2019 Apr 19.

PMID:
31101241
8.

Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome.

López-Jaramillo P, Barbosa E, Molina DI, Sanchez R, Diaz M, Camacho PA, Lanas F, Pasquel M, Accini JL, Ponte-Negretti CI, Alcocer L, Cobos L, Wyss F, Sebba-Barroso W, Coca A, Zanchetti A; Latin American Society of Hypertension Consensus Expert Group.

J Hypertens. 2019 Jun;37(6):1126-1147. doi: 10.1097/HJH.0000000000002072.

PMID:
30882601
9.

'Temporary Plasticiser': A novel solution to fabricate 3D printed patient-centred cardiovascular 'Polypill' architectures.

Pereira BC, Isreb A, Forbes RT, Dores F, Habashy R, Petit JB, Alhnan MA, Oga EF.

Eur J Pharm Biopharm. 2019 Feb;135:94-103. doi: 10.1016/j.ejpb.2018.12.009. Epub 2018 Dec 21.

PMID:
30579852
10.

[The polypill for cardiovascular disease: why is it used so infrequently?]

Bots ML, Lafeber M.

Ned Tijdschr Geneeskd. 2018 Dec 5;162. pii: D3636. Dutch.

PMID:
30570925
11.

Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study.

Pais P, Jung H, Dans A, Zhu J, Liu L, Kamath D, Bosch J, Lonn E, Yusuf S.

Eur J Prev Cardiol. 2019 May;26(7):681-697. doi: 10.1177/2047487318819019. Epub 2018 Dec 11.

PMID:
30537846
12.

Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology.

Sosa-Liprandi Á, Sosa Liprandi MI, Alexánderson E, Avezum Á, Lanas F, López-Jaramillo JP, Martínez F, Ponte-Negretti N CI, Wyss F, González Juanatey JR, Perel P.

Glob Heart. 2019 Mar;14(1):3-16.e1. doi: 10.1016/j.gheart.2018.10.001. Epub 2018 Nov 28. Review.

PMID:
30502220
13.

The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.

Joseph P, Pais P, Dans AL, Bosch J, Xavier D, Lopez-Jaramillo P, Yusoff K, Santoso A, Talukder S, Gamra H, Yeates K, Lopez PC, Tyrwhitt J, Gao P, Teo K, Yusuf S; TIPS-3 Investigators.

Am Heart J. 2018 Dec;206:72-79. doi: 10.1016/j.ahj.2018.07.012. Epub 2018 Aug 2.

14.

Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?

Franczyk B, Gluba-Brzózka A, Jurkiewicz Ł, Penson P, Banach M, Rysz J.

Expert Opin Pharmacother. 2018 Dec;19(17):1857-1865. doi: 10.1080/14656566.2018.1532501. Epub 2018 Oct 9.

PMID:
30295098
15.

Combined use of polypill components in patients with type 2 diabetes mellitus.

Janssen VE, Visseren FL, de Boer A, Grobbee DE, Westerink J, van der Graaf Y, Lafeber M; SMART Study Group.

Eur J Prev Cardiol. 2018 Sep;25(14):1523-1531. doi: 10.1177/2047487318789494. Epub 2018 Jul 23.

PMID:
30033753
16.

Polypill strategy at the heart of cardiovascular secondary prevention.

Ibañez B, Castellano JM, Fuster V.

Heart. 2019 Jan;105(1):9-10. doi: 10.1136/heartjnl-2018-313464. Epub 2018 Jul 20. No abstract available.

PMID:
30030331
17.

Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention.

Marzal D, Rodríguez Padial L, Arnáiz JA, Castro A, Cosín J, Lekuona I, Guijarro C.

Clin Investig Arterioscler. 2018 Sep - Oct;30(5):240-247. doi: 10.1016/j.arteri.2018.04.004. Epub 2018 Jul 17. Review. English, Spanish.

PMID:
30017176
18.

Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials.

Selak V, Webster R, Stepien S, Bullen C, Patel A, Thom S, Arroll B, Bots ML, Brown A, Crengle S, Dorairaj P, Elley CR, Grobbee DE, Harwood M, Hillis GS, Laba TL, Neal B, Peiris D, Rafter N, Reid C, Stanton A, Tonkin A, Usherwood T, Wadham A, Rodgers A.

Heart. 2019 Jan;105(1):42-48. doi: 10.1136/heartjnl-2018-313108. Epub 2018 Jun 28.

19.
20.

Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.

Singh K, Crossan C, Laba TL, Roy A, Hayes A, Salam A, Jan S, Lord J, Tandon N, Rodgers A, Patel A, Thom S, Prabhakaran D.

Int J Cardiol. 2018 Jul 1;262:71-78. doi: 10.1016/j.ijcard.2018.03.082. Epub 2018 Mar 21.

Supplemental Content

Loading ...
Support Center